

May 19, 2024

National Stock Exchange of India Limited
Exchange Plaza, Plot No. C/1, G Block,
Bandra Kurla Complex, Bandra (E),
Mumbai – 400 051.
Symbol: RAINBOW

BSE Limited
Corporate Relationship Department,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001.
Scrip Code: 543524

Sub: Monitoring Agency Report for the Quarter ended March 31, 2024.

Dear Sir/ Madam,

Pursuant to Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Regulation 41 of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, we are enclosing herewith the Monitoring Agency Report dated May 15, 2024, issued by HDFC Bank Limited, Monitoring Agency, for the quarter ended March 31, 2024 in respect of utilization of proceeds of the Initial Public Offer of the Company.

We request you to kindly take the same on record.

Thanking You,

Yours Faithfully,

For **Rainbow Children's Medicare Limited**

Ashish Kapil
Company Secretary and Compliance Officer

Encl.: As above

Rainbow Children's Medicare Limited

Registered Office: 8-2-120/103/1, Survey No. 403, Road No. 2, Banjara Hills, Hyderabad, Telangana - 500034

Corporate Office: 8-2-19/1/a, Daulet Arcade, Karvy Lane, Road No.11, Banjara Hills, Hyderabad, Telangana - 500034

Hyderabad: Banjara Hills - 040 22334455 | Secunderabad - 040 42462200 | Kondapur IP - 040 42462400

Kondapur OP - 040 42462100 | Hyder Nagar - 040 42462300 | L B Nagar - 040 71111333 | Financial District - 1800 2122

Vijayawada: Currency Nagar - 0866 6669666 | Governorpet - 0866 6650250 | **Chennai:** Guindy - 044 40122444 | Sholinganallur - 044 - 69659000

Bengaluru: Marathahalli - 080 42412345 | Bannerghatta Road - 080 25512345 | Hebbal - 080 35061555

Delhi: Malviya Nagar - 011 66888866 | **Visakhapatnam:** Health City, Chinagadili - 0891 3501601 | Siripuram - 0891 3501555



We understand your world



CIN: L65920MH1994PLC080618
Website: www.hdfcbank.com

HDFC Bank Limited,
CMS - Disbursement Team,
Lodha - I Think Techno Campus,
Office Floor 3, Opposite Crompton
Greaves Limited, Next to Kanjurmarg
Railway Station, Kanjurmarg East,
Mumbai - 400 042

SCHEDULE IX

MONITORING REPORT

NAME OF THE MONITORING AGENCY: **HDFC Bank Limited**

MONITORING REPORT FOR THE QUARTER ENDED: **March 2024**

(1) Name of the Issuer: **Rainbow Children's Medicare Limited**


(a) Deviation from the objects: **Not Applicable**

(b) Range of Deviation: **Not Applicable**

Declaration:

We hereby declare that this report is based on the format as prescribed by SEBI (ICDR) Regulation, 2018, as amended. I/We further declare basis the certification issued by the Chartered Accountant appointed by the company that this report provides true and fair view of the utilization of issue proceeds.

We declare that we do not have any direct / indirect interest in or relationship with the issuer/promoters/directors/management and also confirm that we do not perceive any conflict of interest in such relationship / interest while monitoring and reporting the utilization of issue proceeds by the issuer.

Signature: 

Name of the Authorized Person/Signing Authority: **Tushar Gavankar**

Designation of Authorized person/Signing Authority: **Vice President**

Seal of the Monitoring Agency:

Date: **15.05.2024**



1. Issuer Details:

Name of the issuer :	Rainbow Childrens Medicare Limited
Names of the promoter :	Dr. Ramesh Kancharla Dr. Dinesh Kumar Chirra Dr. Adarsh Kancharla
Industry/sector to which it belongs	Health Care

2. Issue Details:

Issue Period	April 27, 2022 to April 29, 2022
Type of issue (public/rights)	INITIAL PUBLIC OFFER ("IPO")
Type of specified securities	EQUITY SHARES
Grading	Not Applicable
Issue size (Rs in Million)	Rs. 15,808.49 Million (Fresh Issue – Rs. 2,800 Million and Offer for Sale – Rs. 13,008.49)

3. Details of the arrangement made to ensure the monitoring of issue proceeds:

(Give item by item description for all the objects stated in the offer document separately in following format)

Particulars	Reply	Comments of CA	Comments of the Monitoring Agency
Whether all the utilization is as per disclosure in Offer Document?	Yes/ No	YES	NA
Whether Shareholder approval is obtained in case of material deviations# from expenditures disclosed in Offer Document?	Yes/ No	NA	NA
Whether means of finance for disclosed objects of the Issue has changed?	Yes/ No	NA	NA
Any major deviation observed over the earlier monitoring agency reports?	Yes/ No	NA	NA
Whether all Government / Statutory approvals related to the object(s) obtained?	Yes/ No	NA	NA
Whether all arrangements pertaining to technical assistance/collaboration in operation?	Yes/ No	NA	NA
Any favorable events improving object(s) viability	Yes/ No	NA	NA
Any unfavorable events affecting object(s) viability	Yes/ No	NA	NA
Any other relevant information that may materially affect the decision making of the investors	Yes/ No	NA	NA

Where material deviation may be defined to mean:

- Deviation in the objects or purposes for which the funds have been raised:
- Deviation in the amount of fund actually utilized by more than 10% of the amount projected in the offer documents.



4. Details of object(s) to be monitored:

Cost of object(s)

(Give Item by Item Description for all the Objects Stated in Offer Document separately in following Format)

Sl. No	Item Head	Source of information/certifications considered by Monitoring Agency for preparation of report	Original Cost (as per Offer Document) (Rs In Millions)	Revised Cost	Comments of Monitoring Agency	Comments of the Board of Directors		
						Reason of cost revision	Proposed financing option	Particulars of firm arrangements made
1	Early redemption of Non-Convertible Debentures (NCDs) issued by the Company to CDC Emerging Markets Limited ("CDCEML")	Prospectus, Monitoring Agency Agreement & Practising Chartered Accountant certificate dated 02nd May, 2022	400.00	400.00	NA	NA	NA	NA
2	Capital expenditure towards setting up of new hospitals and purchase of medical equipment for such new hospitals		1700.00	1700.00	NA	NA	NA	NA
3	General corporate purposes*		561.40	576.10	NA	NA	NA	NA
	Total Cost		2661.40	2676.10				

*During the quarter ended September 2023, the company has received an amount of 14.70 million towards the Company's share of unspent IPO expenses. The Board of directors of the company has approved to spend the amount of Rs. 14.70 million towards the General corporate purposes in the meeting held on 30th Oct 2023. After this change, amount to be utilized for General Corporate purpose is Rs. 576.10 million.



(i) Progress in the object(s)-

Details of IPO proceeds and object wise utilization

(Rs In Millions)

Sl. No	Item Heads	Amount as proposed in Offer Document	Amount utilized			Total unutilized Amount *
			As at Beginning of the quarter (01-Jan-2024)	During the quarter	At the end of the quarter (31-Mar-2024)	
1	Early redemption of Non-Convertible Debentures (NCDs) issued by the Company to CDC Emerging Markets Limited ("CDOEML")	400.00	400.00	0.00	400.00	0.00
2	Capital expenditure towards setting up of new hospitals and purchase of medical equipment for such new hospitals	1700.00				374.93
	(a) Civil, interior and furnishing works		430.51	102.37	532.88	
	(b) Mechanical, electrical and plumbing works		266.90	50.63	317.53	
	(c) Medical infrastructure		83.10	13.63	96.73	
	(d) IT components		31.36	8.41	39.77	
	(e) Medical Equipment		245.57	92.59	338.16	
	Total		1057.44	267.63	1325.07	
3	General corporate purposes*	576.10	576.10	0	576.10	0.00
	Total Cost	2676.10	2033.54	267.63	2301.17	374.93

* During the quarter ended September 2023, the company has received an amount of 14.70 million towards the Company's share of unspent IPO expenses. The Board of directors of the company has approved to spend the amount of Rs. 14.70 million towards the General corporate purposes in the meeting held on 30th Oct 2023. After this change, amount to be utilized for General Corporate purpose is Rs. 576.10 million.

Rs 374.93 million is available in Fixed Deposits and Current Account as detailed below



(ii) Deployment of unutilized IPO proceeds

(Rs in million)

S.No.	Type of Instrument and name of the entity Invested in (Fixed Deposits)	Amount Invested	Date Of Deposit/ Renewed Date
1	HDFC Bank Limited bearing FD no. 50300625275226	0.65	19-May-22
2	HDFC Bank Limited bearing FD no. 50300625736236	19.50	20-May-22
3	HDFC Bank Limited bearing FD no. 50300628360435	19.80	26-May-22
4	HDFC Bank Limited bearing FD no.50300630872840	19.50	2-Jun-22
5	HDFC Bank Limited bearing FD no.50300630880572	19.50	1-Jun-22
6	HDFC Bank Limited bearing FD no.50300636341930	19.50	13-Jun-22
7	HDFC Bank Limited bearing FD no.50300634309113	19.50	6-Jun-22
8	HDFC Bank Limited bearing FD no.50300634337011	19.50	8-Jun-22
9	HDFC Bank Limited bearing FD no.50300772524374	20.00	29-Mar-23
10	HDFC Bank Limited bearing FD no.50300772525150	20.00	29-Mar-23
11	HDFC Bank Limited bearing FD no.50300772525720	20.00	29-Mar-23
12	HDFC Bank Limited bearing FD no.50300772526302	20.00	29-Mar-23
13	HDFC Bank Limited bearing FD no.50300772527624	20.00	29-Mar-23
14	HDFC Bank Limited bearing FD no.50300772528222	20.00	29-Mar-23
15	HDFC Bank Limited bearing FD no.50300772536228	45.00	29-Mar-23
16	HDFC Bank Limited bearing FD no.50300772536741	45.00	29-Mar-23
17	HDFC Bank Limited bearing FD no.50300772537260	45.00	29-Mar-23
	Total amount in Fixed Deposits (including Interest and Excluding Accumulated Interest)	392.45	
18	Amount in Current Account with HDFC Bank, Banjarahills, Hyderabad	0.26	
	Total Funds	392.71	

(iii) Delay in implementation of the object(s)-

Sl. No	Object(s) Name	Status as on 31st Mar 2024		Delay (No of Days/Months)	Comments of Management	
		As per Offer document	Actuals		Reason of delay	Proposed Course of action
1	Capital expenditure towards setting up of new hospitals and purchase of medical equipment for such new hospitals	1500	1325.07	NA	Delay in execution of few projects	We will utilise the same in FY25

(iv) * In case of continuing object(s) please specify latest/revised estimate of completion date.



(i) Details of utilization of proceeds stated as General Corporate Purpose (GCP) amount in the offer document:

(Rs in million)

Item Head	Amount as per offer document (Revised)	Amount Utilized as on 31st March 2024	Un Utilised Balance
General corporate purposes	576.10	576.10	0.00

